Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351037 · ClinicalTrials.gov registry record · Phase 2
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02351037 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 36 participants.
The verdict
NCT02351037, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib alone or in combination with either cytarabine or azacitidine in the treatment of subjects with Acute Myeloid Leukemia (AML) who have failed standard treatment, or subjects without prior therapy who refuse standard chemotherapy.
Interventions
- DRUG Ibrutinib
- DRUG Ibrutinib + LD-AraC
- DRUG Ibrutinib+Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02351037
The ClinicalTrials.gov registry entry for NCT02351037 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ibrutinib is the first listed.
NCT02351037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02351037 about?
NCT02351037 is a clinical study titled "Study of Ibrutinib in Subjects With Acute Myeloid Leukemia". The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib alone or in combination with either cytarabine or azacitidine in the treatment of subjects with Acute Myeloid Leukemia (AML) who have failed standard treatment, or subjects without prior therapy who refuse st...
What is the current status of trial NCT02351037?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-02. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02351037?
The interventions under investigation include: Ibrutinib (DRUG), Ibrutinib + LD-AraC (DRUG), Ibrutinib+Azacitidine (DRUG).
Who is sponsoring clinical trial NCT02351037?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.